9,428 reports of this reaction
11.0% of all NINTEDANIB reports
#1 most reported adverse reaction
DIARRHOEA is the #1 most commonly reported adverse reaction for NINTEDANIB, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 9,428 FDA adverse event reports linking NINTEDANIB to DIARRHOEA. This represents approximately 11.0% of all 85,660 adverse event reports for this drug.
NINTEDANIB has an overall safety score of 85 out of 100. Patients taking NINTEDANIB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is a frequently reported adverse event for NINTEDANIB, accounting for a significant proportion of all reports.
In addition to diarrhoea, the following adverse reactions have been reported for NINTEDANIB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 9,428 FDA reports for NINTEDANIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 11.0% of all adverse event reports for NINTEDANIB, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking NINTEDANIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.